(0.91%) 5 063.98 points
(0.88%) 38 235 points
(1.46%) 15 834 points
(0.15%) $79.12
(5.85%) $2.05
(0.26%) $2 316.90
(0.64%) $26.92
(1.13%) $965.65
(-0.07%) $0.932
(-0.37%) $10.99
(-0.07%) $0.798
(-1.37%) $91.98
Live Chart Being Loaded With Signals
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally...
Stats | |
---|---|
Today's Volume | 1.17M |
Average Volume | 842 586 |
Market Cap | 275.02B |
EPS | INR0 ( 2024-04-25 ) |
Next earnings date | ( INR1.800 ) 2024-07-24 |
Last Dividend | INR0.750 ( 2023-06-30 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 54.20 |
ATR14 | INR0.463 (0.07%) |
Volume Correlation
Syngene International Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Syngene International Correlation - Currency/Commodity
Syngene International Financials
Annual | 2023 |
Revenue: | INR34.89B |
Gross Profit: | INR12.44B (35.65 %) |
EPS: | INR12.71 |
FY | 2023 |
Revenue: | INR34.89B |
Gross Profit: | INR12.44B (35.65 %) |
EPS: | INR12.71 |
FY | 2022 |
Revenue: | INR31.93B |
Gross Profit: | INR23.33B (73.06 %) |
EPS: | INR11.59 |
FY | 2022 |
Revenue: | INR25.07B |
Gross Profit: | INR17.58B (70.12 %) |
EPS: | INR9.94 |
Financial Reports:
No articles found.
Syngene International Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0.750 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.500 | 2016-03-17 |
Last Dividend | INR0.750 | 2023-06-30 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 6 | -- |
Total Paid Out | INR3.25 | -- |
Avg. Dividend % Per Year | 0.05% | -- |
Score | 2.57 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 3.39 | |
Div. Directional Score | 7.65 | -- |
Year | Amount | Yield |
---|---|---|
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0.500 | 0.16% |
2019 | INR0.500 | 0.18% |
2020 | INR0 | 0.00% |
2021 | INR0 | 0.00% |
2022 | INR0.500 | 0.08% |
2023 | INR0.750 | 0.13% |
2024 | INR0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SMLT.NS | Dividend Knight | 2023-08-09 | Semi-Annually | 3 | 0.64% | |
MIDHANI.NS | Dividend Junior | 2023-09-22 | Semi-Annually | 7 | 1.04% | |
HAVELLS.NS | Dividend Junior | 2023-06-02 | Annually | 23 | 0.43% | |
BECTORFOOD.NS | Dividend Junior | 2023-09-22 | Semi-Annually | 4 | 0.39% | |
PUNJABCHEM.NS | Dividend Junior | 2023-07-27 | Sporadic | 18 | 0.16% | |
KENNAMET.NS | Dividend Knight | 2023-05-25 | Annually | 4 | 0.76% | |
ELECTCAST.NS | Dividend Junior | 2023-09-04 | Annually | 23 | 1.51% | |
AHLUCONT.NS | Dividend Junior | 2023-09-22 | Sporadic | 15 | 0.04% | |
SUNPHARMA.NS | Dividend Knight | 2023-07-28 | Semi-Annually | 29 | 0.77% | |
NAVA.NS | Dividend Junior | 2023-07-24 | Annually | 23 | 2.35% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.146 | 1.500 | 7.08 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0829 | 1.200 | 7.24 | 8.68 | [0 - 0.3] |
returnOnEquityTTM | 0.127 | 1.500 | 9.70 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.712 | 0.800 | 6.44 | 5.15 | [1 - 3] |
quickRatioTTM | 1.327 | 0.800 | 6.90 | 5.52 | [0.8 - 2.5] |
cashRatioTTM | 0.492 | 1.500 | 8.38 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0309 | -1.500 | 9.48 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 14.26 | 1.000 | 5.83 | 5.83 | [3 - 30] |
operatingCashFlowPerShareTTM | 20.51 | 2.00 | 3.16 | 6.33 | [0 - 30] |
freeCashFlowPerShareTTM | 20.51 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0446 | -1.500 | 9.82 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.636 | 1.000 | 2.73 | 2.73 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.193 | 1.000 | 8.14 | 8.14 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 4.32 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.567 | 0.800 | 9.55 | 7.64 | [0.5 - 2] |
Total Score | 11.90 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 53.97 | 1.000 | 4.65 | 0 | [1 - 100] |
returnOnEquityTTM | 0.127 | 2.50 | 9.80 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 20.51 | 2.00 | 3.16 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.109 | 1.500 | 7.27 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 20.51 | 2.00 | 3.16 | 6.33 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -22.89 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.235 | 1.000 | 6.62 | 0 | [0.1 - 0.5] |
Total Score | 3.39 |
Syngene International
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally. The company provides discovery chemistry services, such as medicinal and synthetic chemistry, library and peptide synthesis, biomolecules, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals. It also offers exploratory/discovery, in vitro and genetic, and developmental and reproductive toxicology services, as well as acute, sub-chronic, and chronic toxicity studies; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. In addition, the company provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, biometrics and clinical data management, regulatory, medical monitoring, pharmacovigilance, and medical writing services. Further, it offers other drug modalities, which include peptides, oligonucleotide synthesis, antibody drug conjugate, PROTACs, and CAR T-cell therapy services. The company serves pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and other companies. It has partnerships and collaborations with Bristol-Myers Squibb Co.; Baxter Inc.; and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators